医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Evaluate Ltd. appoints Martyn Hindley as Chief Financial Officer

2019年12月10日 AM12:36
このエントリーをはてなブックマークに追加


 

LONDON & BOSTON & TOKYO

Evaluate Ltd., the leading provider of commercial data to the life sciences industry, is pleased to announce the appointment of Martyn Hindley as Chief Financial Officer, effective from today. Martyn succeeds Nick Southwell, who joined Evaluate as Interim CFO in December 2016, prior to being appointed as CFO in September 2017.

Martyn brings over 30 years of senior financial experience to Evaluate, with a focus on technology-driven, international, and multi-sector corporations. He most recently served as CFO of Global Reach Group, and also held executive roles at Equiniti Group Ltd., Quadriga Worldwide Ltd, Aquascutum and Emap International Ltd.

“I’m excited and honoured to be joining Evaluate at such a momentous time in their company trajectory,” said Martyn. “They continue to expand their leadership in the pharmaceutical industry by capitalizing on cutting-edge technologies, and as a result are delivering truly breakthrough offerings. I look forward to helping their team drive growth through smart business and financial strategies.”

“We’re delighted to welcome Martyn to Evaluate,” said Deborah Kobewka, CEO. “His strong record of creating commercial value through transformational leadership strongly aligns with our ongoing commitment to delivering excellence and innovation to our clients and partners, and I look forward to his contributions as part of our executive leadership team.”

About Evaluate Ltd.

Evaluate provides trusted commercial intelligence for the pharmaceutical industry and their advisors. Our EvaluatePharma® and EvaluatePharma Vision platforms provide complete and dynamic asset valuations alongside a seamless, comprehensive view of the global market.

Vantage – our award-winning, independent editorial team – provides thought-provoking news and analysis of current and future industry developments.

Evaluate has been a partner to industry-leading organisations for over 20 years. For more information on how we radically transform our clients’ confidence in strategic portfolio decisions, visit www.evaluate.com.

Follow us on Twitter: @EvaluatePharma, @EvaluateMedtech, @Vantageanalysis

View source version on businesswire.com: https://www.businesswire.com/news/home/20191209005552/en/

CONTACT

Evaluate Ltd.

Jennifer Dinkel

+1 617-936-7783

jennifer.dinkel@evaluate.com

同じカテゴリーの記事 

  • Hyperfine, Inc. Takes the Stage at ISMRM with Seventeen Abstracts Assessing the Potential of Using Swoop® System Images Across Multiple Care Settings and Clinical Conditions
  • ReNAgade Therapeutics宣布在ASGCT第27届年会上发表演讲
  • ReNAgade TherapeuticsがASGCT第27回年次総会でのプレゼンテーションの内容を発表
  • BeiGene Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer
  • The 2024 Japan Prize Award Ceremony Is Held with Their Majesties the Emperor and Empress of Japan in Attendance